Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients
Biologic License Application submission expected for 2025
https://www.hansabiopharma.com/media/press-releases/2023/update-on-confides-phase-3-trial-of-imlifidase-in-highly-sensitized-kidney-transplant-patients/
"ConfIdeS trial is expected to conclude in mid-2024."
"To accelerate randomization, Hansa has increased overall site activation up to 25 sites, continued enrollment beyond the targeted 64 patients, ..."
Tjek også: Clinical pipeline update & Commercial update.
"Total cash and equivalents stood at SEK 908 million (USD 83m) end of September 2023 which is expected to finance Hansa’s operations into 2025, as previously guided."
Biologic License Application submission expected for 2025
https://www.hansabiopharma.com/media/press-releases/2023/update-on-confides-phase-3-trial-of-imlifidase-in-highly-sensitized-kidney-transplant-patients/
"ConfIdeS trial is expected to conclude in mid-2024."
"To accelerate randomization, Hansa has increased overall site activation up to 25 sites, continued enrollment beyond the targeted 64 patients, ..."
Tjek også: Clinical pipeline update & Commercial update.
"Total cash and equivalents stood at SEK 908 million (USD 83m) end of September 2023 which is expected to finance Hansa’s operations into 2025, as previously guided."
